Spyre Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Spyre Therapeutics (SYRE).

Price Target Range — 12 Quarters

Analyst Consensus — 17 Analysts

1S.Buy

16Buy

Consensus RatingBuy# Analysts17Avg. Consensus PT$101Upside to Avg. PT+10.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	BTIG	Julian Harrison	Maintained	Buy	$121
Oct 12, 2026	UBS	Alice Nettleton	Initiate	Buy	$120
Oct 1, 2026	JP Morgan	Hardik Parikh	Initiate	Overweight	$110
Oct 1, 2026	BTIG	Julian Harrison	Maintained	Buy	$121
Sep 9, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$123
Sep 8, 2026	BTIG	Julian Harrison	Maintained	Buy	$121
Aug 26, 2026	Deutsche Bank	David Hoang	PT Cut	Buy	$135→$127
Aug 26, 2026	Wedbush	David Nierengarten	PT Cut	Outperform	$130→$123
Aug 26, 2026	BTIG	Julian Harrison	PT Cut	Buy	$132→$121
Aug 11, 2026	BTIG	Julian Harrison	PT Raise	Buy	$112→$132
Aug 5, 2026	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$90→$115
Aug 5, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$115→$130
Aug 5, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$100→$130
Jul 28, 2026	Wolfe Research	Andy Chen	Downgrade	Outperform→Peer Perform	—
Jul 13, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$84→$120
Jun 23, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$115→$135
Jun 15, 2026	BTIG	Julian Harrison	PT Raise	Buy	$98→$112
Jun 4, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$102→$115
May 6, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$64→$97
May 6, 2026	Stifel	Alex Thompson	PT Raise	Buy	$92→$107

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.

Benzinga Newsdesk

PRO
UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120

UBS analyst Alice Nettleton initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Buy rating and announces Price Target of $120.

Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110

JP Morgan analyst Hardik Parikh initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Overweight rating and announces Price Target of $110.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target

Wedbush analyst David Nierengarten reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and maintains $123 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.

Benzinga Newsdesk

Spyre Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Spyre Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

PRO
UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120

PRO
JP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

PRO
Wedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

People Also Watch

People Also Watch

Spyre Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Spyre Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

PROUBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120

PROJP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110

PROBTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

PROWedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target

PROBTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

People Also Watch

People Also Watch

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

PRO
UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120

PRO
JP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

PRO
Wedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target